Shots:

• The approval is based on ORIENT-1 study results assessing Tyvyt in patients with 2L+ Hodgkin's lymphoma
• The ORIENT-1 study resulted in effective complete response rates for CT + radiotherapy in patients
• Tyvyt is an IgG4 mAb- which helps in binding with PD-1 in T cells further blocking PD-L1. In 2015- Innovent Biologics and Eli Lilly collaborated to jointly develop and commercialize Tyvyt in China

  Ref: Innovent Biologics | Image: Eli Lilly